Research ArticleOncology
Preclinical Development of CD38-Targeted [89Zr]Zr-DFO-Daratumumab for Imaging Multiple Myeloma
Anchal Ghai, Dolonchampa Maji, Nicholas Cho, Chantiya Chanswangphuwana, Michael Rettig, Duanwen Shen, John DiPersio, Walter Akers, Farrokh Dehdashti, Samuel Achilefu, Ravi Vij and Monica Shokeen
Journal of Nuclear Medicine February 2018, 59 (2) 216-222; DOI: https://doi.org/10.2967/jnumed.117.196063
Anchal Ghai
1Department of Radiology, Washington University School of Medicine, St. Louis, Missouri
Dolonchampa Maji
1Department of Radiology, Washington University School of Medicine, St. Louis, Missouri
2Department of Biomedical Engineering, Washington University in St. Louis, St. Louis, Missouri
Nicholas Cho
1Department of Radiology, Washington University School of Medicine, St. Louis, Missouri
2Department of Biomedical Engineering, Washington University in St. Louis, St. Louis, Missouri
Chantiya Chanswangphuwana
3Department of Medicine, Washington University School of Medicine, St. Louis, Missouri
Michael Rettig
3Department of Medicine, Washington University School of Medicine, St. Louis, Missouri
Duanwen Shen
1Department of Radiology, Washington University School of Medicine, St. Louis, Missouri
John DiPersio
3Department of Medicine, Washington University School of Medicine, St. Louis, Missouri
Walter Akers
4Center for In Vivo Imaging and Therapeutics, St. Jude Children’s Research Hospital, Memphis, Tennessee; and
Farrokh Dehdashti
1Department of Radiology, Washington University School of Medicine, St. Louis, Missouri
Samuel Achilefu
1Department of Radiology, Washington University School of Medicine, St. Louis, Missouri
2Department of Biomedical Engineering, Washington University in St. Louis, St. Louis, Missouri
5Department of Biochemistry and Molecular Biophysics, Washington University School of Medicine, St. Louis, Missouri
Ravi Vij
3Department of Medicine, Washington University School of Medicine, St. Louis, Missouri
Monica Shokeen
1Department of Radiology, Washington University School of Medicine, St. Louis, Missouri
2Department of Biomedical Engineering, Washington University in St. Louis, St. Louis, Missouri
Data supplements
Supplemental Data
Files in this Data Supplement:
In this issue
Journal of Nuclear Medicine
Vol. 59, Issue 2
February 1, 2018
Preclinical Development of CD38-Targeted [89Zr]Zr-DFO-Daratumumab for Imaging Multiple Myeloma
Anchal Ghai, Dolonchampa Maji, Nicholas Cho, Chantiya Chanswangphuwana, Michael Rettig, Duanwen Shen, John DiPersio, Walter Akers, Farrokh Dehdashti, Samuel Achilefu, Ravi Vij, Monica Shokeen
Journal of Nuclear Medicine Feb 2018, 59 (2) 216-222; DOI: 10.2967/jnumed.117.196063
Preclinical Development of CD38-Targeted [89Zr]Zr-DFO-Daratumumab for Imaging Multiple Myeloma
Anchal Ghai, Dolonchampa Maji, Nicholas Cho, Chantiya Chanswangphuwana, Michael Rettig, Duanwen Shen, John DiPersio, Walter Akers, Farrokh Dehdashti, Samuel Achilefu, Ravi Vij, Monica Shokeen
Journal of Nuclear Medicine Feb 2018, 59 (2) 216-222; DOI: 10.2967/jnumed.117.196063
Jump to section
Related Articles
Cited By...
- A Gallium-68-Labeled Peptide Radiotracer For CD38-Targeted Imaging In Multiple Myeloma With PET
- A GALLIUM-68-LABELED PEPTIDE RADIOTRACER FOR CD38-TARGETED IMAGING IN MULTIPLE MYELOMA WITH PET
- First-in-Humans Evaluation of Safety and Dosimetry of 64Cu-LLP2A for PET Imaging
- Minimal Residual Disease in Myeloma: Application for Clinical Care and New Drug Registration
- Mars Shot for Nuclear Medicine, Molecular Imaging, and Molecularly Targeted Radiopharmaceutical Therapy
- 212Pb {alpha}-Radioimmunotherapy Targeting CD38 in Multiple Myeloma: A Preclinical Study
- Poly(ADP-Ribose) Polymerases in Host-Pathogen Interactions, Inflammation, and Immunity